{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-23-000068","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.453490+00:00","generated_at":"2026-06-09T08:01:37.913528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bio-Rad Q3 net sales down 7.1% YoY to $632.1M; lowers full-year 2023 outlook","bullets":["Net sales $632.1M, down 7.1% YoY; currency-neutral decline 7.9%; COVID sales dropped to $0.3M from $17.2M.","Life Science segment sales $263.5M, down 17.1% YoY (currency-neutral -17.8%); diagnostics segment up 1.7%.","Net income $106.3M ($3.64 diluted EPS) vs net loss of $162.8M ($5.48 loss) in prior year, driven by Sartorius fair value changes.","Operating income $90.9M vs $94.6M; gross margin 53.1% vs 54.7%.","CEO cites further deterioration in biopharma/biotech spending and China challenges; full-year FY2023 outlook lowered."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-23-000068","json":"https://secwatch.observer/filing/0000012208-23-000068.json","markdown":"https://secwatch.observer/filing/0000012208-23-000068.md","text":"https://secwatch.observer/filing/0000012208-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/0000012208-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/bio-20231026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:01:37.913528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d0347818eefbe7e5b78f4f15cb1f02508cfa8b6","claim":"BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2023 results: revenue $632.1 million, net income $106.3 million, EPS $3.64 per share. Guidance lowered.","evidence_excerpt":"life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.9 percent compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000068/0000012208-23-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$632.1 million"},{"label":"Net income","value":"$106.3 million"},{"label":"EPS","value":"$3.64 per share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}